Skip to main content
    1

    10X Genomics Inc (TXG)

    Official site

    HEALTHCARE • HEALTH INFORMATION SERVICES • NASDAQ

    $73.10
    +1.31 (+1.82%)

    Market Cap: $9.52B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    69%(20/29)
    Avg Surprise
    +19.17%
    Streak
    6 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.02
    Range$-0.04 - $0.00
    2 analysts
    EPS Revisions
    2
    0
    7d
    2
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.04+45.5%
    60d ago$-0.04+45.5%
    30d ago$-0.02-19.8%
    7d ago$-0.02-19.8%
    Current$-0.02
    Revenue Consensus
    $148M
    Range$146M - $152M
    16 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.13
    Range$-0.00 - $0.28
    3 analysts
    Revenue Consensus
    $180M
    Range$176M - $186M
    17 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.13---
    Sep 26EST
    		-$-0.02---
    Jun 26
    Reported Aug 6
    		$-0.14$-0.23+39.13%Beat-150.0%
    Mar 26
    Reported May 7
    		$0.07$-0.06+216.67%Beat+170.0%
    Dec 25
    Reported Feb 12
    		$0.07$-0.04+275.00%Beat+150.0%
    Sep 25
    Reported Nov 6
    		$-0.02N/A+71.43%Beat+0.0%
    Jun 25
    Reported Aug 7
    		$0.28$-0.35+180.00%Beat+2700.0%
    Mar 25
    Reported May 8
    		$-0.10N/A+65.52%Beat+50.0%
    Dec 24
    Reported Feb 12
    		$-0.14$-0.11-27.27%Miss+65.9%
    Sep 24
    Reported Oct 29
    		$-0.02N/A+92.31%Beat+80.0%
    Jun 24
    Reported Aug 8
    		$0.01N/A+104.35%Beat+107.1%
    Mar 24
    Reported Apr 30
    		$-0.20$-0.39+48.72%Beat-185.7%
    Dec 23
    Reported Feb 15
    		$-0.41$-0.36-13.89%Miss-295.2%
    Sep 23
    Reported Nov 2
    		$-0.10$-0.04-150.00%Miss-42.9%
    Jun 23
    Reported Aug 3
    		$-0.14$-0.05-180.00%Miss+44.0%
    Mar 23
    Reported May 3
    		$-0.07N/A+56.25%Beat+50.0%
    Dec 22
    Reported Feb 15
    		$0.21$-0.20+205.00%Beat+231.3%
    Sep 22
    Reported Nov 2
    		$-0.07N/A+70.83%Beat+53.3%
    Jun 22
    Reported Aug 8
    		$-0.25$-0.30+16.67%Beat-127.3%
    Mar 22
    Reported May 4
    		$-0.14N/A+57.58%Beat-27.3%
    Dec 21
    Reported Feb 16
    		$-0.16$-0.03-433.33%Miss-100.0%
    Sep 21
    Reported Nov 3
    		$-0.15$-0.21+28.57%Beat+40.0%
    Jun 21
    Reported Aug 4
    		$-0.11N/A+52.17%Beat+73.2%
    Mar 21
    Reported May 5
    		$-0.11$-0.19+42.11%Beat+45.0%
    Dec 20
    Reported Feb 17
    		$-0.08$-0.07-14.29%Miss-14.3%
    Sep 20
    Reported Nov 10
    		$-0.25$-0.31+19.35%Beat+24.2%
    Jun 20
    Reported Aug 11
    		$-0.41$-0.49+16.33%Beat-156.2%
    Mar 20
    Reported May 11
    		$-0.20$-0.13-53.85%Miss-
    Dec 19
    Reported Feb 18
    		$-0.07$-0.13+46.15%Beat-
    Sep 19
    Reported Nov 7
    		$-0.33$-0.10-230.00%Miss-
    Jun 19
    Reported Sep 11
    		$-0.16$-0.11-45.45%Miss-

    Key Metrics

    Valuation
    P/E Ratio-3655.00EV/EBITDAN/A
    Price/FCF78.25xFCF Yield1.28%
    Profitability
    Profit Margin-12.20%Operating Margin-15.20%
    ROE-9.40%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio5.69xQuick Ratio5.25x
    Trading Statistics
    Beta1.99Avg Volume4.11M
    52-Week High$102.8152-Week Low$11.80

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$81.48
    SMA 20$82.12
    SMA 50$69.91
    SMA 200$37.26
    EMA 10$78.54
    EMA 20$78.63
    EMA 50$70.23
    EMA 200$43.94

    MACD

    Line: 1.72Signal: 4.33Hist: -2.62

    ADX

    ADX: 35.5+DI: 22.1-DI: 29.0

    Aroon & PSAR

    Aroon Up76.0
    Aroon DownN/A
    PSAR$94.89

    Bollinger Bands

    Upper Band$96.75
    Lower Band$67.50
    %B Position3562%(Upper)
    Band Width0.19

    RSI (14-Day)

    Neutral
    45.6

    Momentum Oscillators

    Stoch %K9.8
    Stoch %D15.5
    Williams %R-86.5
    ROC (10d)-19.1%
    Momentum-17.26
    CCI (20d)-112.6
    MFI (14d)40.4

    Volatility Measures

    ATR (14d)$6.69(9.2%)
    StdDev (20d)7.31
    Hist Vol97.2%(High)

    Volume Flow

    VWAP$71.96
    OBV131.9M
    AD Line122.2M
    CMF (20d)-0.034

    Volume Metrics

    Avg Vol (20d)4.2M
    Vol Ratio1.0x
    VWMA (20d)$81.27

    Pivot Points

    R3$77.11
    R2$75.83
    R1$73.81
    Pivot Point$72.53
    S1$70.51
    S2$69.23
    S3$67.21

    Advanced Oscillators

    TSI8.19
    Ultimate Osc39.7
    KST235.88

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$151.04M$150.84M$166.03M$149.00M$172.91M$154.88M$165.02M$151.65M$153.10M$141.01M$183.98M$153.64M
    Cost of Revenue$38.54M$44.66M$52.98M$48.70M$47.82M$49.44M$54.07M$45.26M$48.88M$48.09M$68.20M$58.12M
    Gross Profit$112.50M$106.18M$113.05M$100.31M$125.08M$105.44M$110.95M$106.39M$104.22M$92.91M$115.78M$95.53M
    Operating Expenses$132.05M$123.22M$132.59M$132.55M$94.96M$144.77M$160.79M$147.88M$145.96M$154.41M$170.97M$190.32M
    R&D$56.79M$56.85M$55.97M$57.19M$61.22M$64.25M$66.97M$66.17M$62.92M$68.64M$84.84M$107.91M
    SG&A$78.66M$66.38M$76.62M$75.36M$74.43M$89.73M$93.83M$81.70M$83.04M$85.77M$86.13M$82.42M
    Operating Income$-19,555,000$-17,046,000$-19,541,000$-32,242,000$30.13M$-39,328,000$-49,839,000$-41,485,000$-41,737,000$-61,498,000$-55,188,000$-94,795,000
    Interest Income$4.80M$5.01M$6.89M$5.20M$4.27M$3.69M$4.51M$4.97M$4.71M$4.74M$4.62M$4.30M
    Interest Expense$0$0$0$-3,000$3,000$0$0$2,000$1,000$1,000$0$0
    Income Before Tax$-18,645,000$-12,847,000$-15,193,000$-28,205,000$37.00M$-33,506,000$-48,380,000$-34,438,000$-37,079,000$-57,803,000$-46,598,000$-91,744,000
    Income Tax Expense$-714,000$623,000$1.06M$-733,000$2.46M$852,000$648,000$1.31M$818,000$2.15M$2.35M$1.24M
    Net Income$-17,931,000$-13,470,000$-16,252,000$-27,472,000$34.54M$-34,358,000$-49,028,000$-35,753,000$-37,897,000$-59,949,000$-48,952,000$-92,986,000
    EBITDA$-13,778,000$-5,951,000$-9,985,000$-21,156,000$42.38M$-27,378,000$-42,324,000$-28,657,000$-30,893,000$-51,044,000$-39,500,000$-84,623,000
    EBIT$-23,442,000$-17,861,000$-22,085,000$-33,407,000$32.73M$-37,192,000$-52,888,000$-39,407,000$-41,793,000$-62,538,000$-51,206,000$-96,043,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about TXG

    Government Contracts

    Gov Obligations (TTM)
    $6.69M
    Gov Obligations / Revenue
    1.0%
    Obligations YoY
    -29.1%
    Active Awards
    99
    New Awards (TTM)
    88
    Avg Remaining Term
    7.5 mo

    Top agency: Department of Health and Human Services at 77.2% of trailing twelve month obligations across 4 agencies

    Recent Awards

    Award IDAgencyObligatedStart
    36C24126P0349Department of Veterans AffairsDepartment of Veterans Affairs$349999Jun 15, 2026
    36C24225P1431Department of Veterans AffairsDepartment of Veterans Affairs$334143Sep 10, 2025
    75N95D25F40047Department of Health and Human ServicesNational Institutes of Health$249991Sep 25, 2025
    75N93025P01086Department of Health and Human ServicesNational Institutes of Health$249964Sep 29, 2025
    75N95D25F40028Department of Health and Human ServicesNational Institutes of Health$249934Aug 18, 2025
    75N95D25F40044Department of Health and Human ServicesNational Institutes of Health$249785Sep 24, 2025
    75N95D25F40021Department of Health and Human ServicesNational Institutes of Health$247506Aug 1, 2025
    75N95D25F40045Department of Health and Human ServicesNational Institutes of Health$246535Sep 25, 2025
    75N95D25F40029Department of Health and Human ServicesNational Institutes of Health$243284Aug 18, 2025
    75N95D25F40035Department of Health and Human ServicesNational Institutes of Health$208360Sep 19, 2025

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Average basic shares outstanding of 10x Genomics Inc Class A – HAN:1KJ

    This page provides financial data, specifically the average basic shares outstanding, for 10x Genomics Inc Class A (HAN:1KJ) traded on the Hannover Stock Exchange. The market was closed at the time of viewing...

    TradingView•10/12/26•Neutral

    ARK and Catherine D. Wood report ownership above 5% in 10x Genomics (TXG).

    ARK Investment Management LLC and Catherine D. Wood have reported a beneficial ownership of 5.22% in 10x Genomics (TXG), totaling 6,272,998 Class A common shares as of September 30, 2026. The SEC filing...

    Stock Titan•10/7/26•Neutral

    Return on assets % of 10x Genomics Inc Class A – HAN:1KJ

    The article provides financial data specifically focusing on the "Return on assets %" for 10x Genomics Inc Class A (HAN:1KJ)...

    TradingView•9/29/26•Neutral

    Gross margin % of 10x Genomics Inc Class A – HAN:1KJ

    The article presents the gross margin percentage for 10x Genomics Inc Class A, traded on the Hannover Stock Exchange under the ticker 1KJ. It indicates that the market is currently closed with no trades recorded....

    TradingView•9/29/26•Neutral

    10x genomics director Shehnaaz Suliman sells $464,667 in stock

    Shehnaaz Suliman, a director at 10x Genomics Inc. (NASDAQ:TXG), sold 5,723 shares of company stock for approximately $464,667 on September 22, 2026...

    Investing.com•9/25/26•Bearish

    TXG Valuation and Fair Value

    P/E
    -3655.0x
    Forward P/E
    1250.0x
    P/FCF
    78.2x
    P/B
    11.5x
    See GNG's fair value

    TXG Profitability: Margins, ROIC and FCF

    Gross margin
    70.0%
    Operating margin
    -15.2%
    Net margin
    -12.2%
    ROE
    -9.4%
    FCF margin
    19.7%
    FCF yield
    1.3%

    TXG Competitors

    CompanyTicker
    Henry Schein IncHSIC
    Qiagen NVQGEN
    Krystal Biotech IncKRYS
    Insulet CorporationPODD
    Bio-Rad Laboratories IncBIO
    Protagonist Therapeutics IncPTGX
    Nuvalent IncNUVL
    Cytokinetics IncCYTK

    Sector: Healthcare

    TXG Analyst Ratings

    Consensus
    Hold
    Analysts
    19
    Strong Buy
    1
    Buy
    6
    Hold
    12
    Sell
    0
    Strong Sell
    0

    TXG Bull Case vs Bear Case

    Bull case

    • TXG converts 19.7% of revenue into free cash flow.
    • TXG beat EPS estimates in 87.5% of its last 8 reported quarters.

    Bear case

    • TXG has a -12.2% net profit margin.
    • TXG's quarterly revenue changed -12.7% year over year.

    TXG Earnings: Beat Rate and Next Report

    Beat rate
    7 of 8 quarters (87.5%)
    Average surprise
    114.1%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.02
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    2 up, 0 down

    Frequently Asked Questions About TXG

    Does TXG pay dividends?

    10X Genomics Inc (TXG) does not currently pay a regular dividend.

    What is TXG's market cap?

    10X Genomics Inc (TXG) has a market capitalization of $9.52B with a current stock price of $73.10.

    Related stocks

    Sector: Healthcare

    All stocks starting with T

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In